期刊文献+

游离循环DNA以及联合应用直肠指诊和经直肠超声检查诊断前列腺癌的临床价值

Diagnostic value of digital rectal examination,free circulating DNA and transrectal ultrasound method for prostate cancer
下载PDF
导出
摘要 目的探讨游离循环DNA(cf-DNA)以及联合应用直肠指诊(DRE)和经直肠超声(TRUS)检查对前列腺癌的诊断价值。方法对93例可疑前列腺癌患者进行DRE、cf-DNA、TRUS检查并与术后病理结果对照,比较三种检查方法单独应用、两者联合应用及三者联合应用对前列腺癌的诊断价值。结果前列腺癌、前列腺良性病变和对照组血清cf-DNA的浓度分别是中位数1223.2ng/ml、153.2ng/ml和118.3ng/ml,三者依次减低,差异有统计学意义(P<0.001);cf-DNA+TRUS+DRE的联合检测方法的敏感性为90.6%,均高于cf-DNA、TRUS和DRE,差异有统计学意义(P<0.05);联合检测特异性也高于cf-DNA、TRUS和DRE,差异有统计学意义(P<0.05),但与TRUS特异性差异无统计学意义(P>0.05)。结论联合应用DRE、cf-DNA、TRUS对提高前列腺癌的诊断具有重要临床价值。 Objective To investigate the diagnostic value of free circulating DNA (cf-DNA) and its combination with digital rectal examination (DRE), and transrectal ultrasound (TRUS) method for prostate cancer. Methods Ninty-three suspected patients of prostate cancer were all examined by DRE, cf-DNA and TRUS. The diagnostic value of the three methods alone, combination of the two and the combination diagnosis of the three were evaluated. Results The median concentration for prostate cancer group, non-prostate cancer group and healthy control group were 1223.2 ng/ml, 153.2 ng/ml and 118.3 ng/ml. There was significant difference among the three groups (P 〈 0.001 ). The sensitivity for combined method of cf-DNA,TRUS and DRE was 90.6%, which was higher than that of cf-DNA, TRUS or DRE alone, which was statistically significant(P 〈 0.05) ; the specificity of combined detection was also higher than that of cf-DNA and DRE, which was also significant (P 〈 0.05), but not for TRUS. Conclusion The combined application of digital rectal examination, cf-DNA and transrectal ultrasonography is clinically important for prostate cancer diagnosis.
出处 《临床超声医学杂志》 2013年第8期533-535,共3页 Journal of Clinical Ultrasound in Medicine
基金 国家自然基金基金项目(81271920/H2005) 南通市社会发展基金(S2010021) 江苏省医学创新团队与领军人才项目(LJ201133)
关键词 超声检查 经直肠 前列腺癌 游离循环DNA Ultrasonography, transrectal Prostate cancer Circulating free DNA
  • 相关文献

参考文献14

  • 1Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 2011, 61(4) :212-236.
  • 2Chimonidou M, Strati A, Malamos N, et al. SOX17 promoter methylation in circulating tumor ceils and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem, 2013, 59( 1 ) :270-279.
  • 3Maeher H, Egea-Guerrero JJ, Revueho-Rey J, et al. Role of early cell-free DNA levels decrease as a predictive marker of fatal outcome after severe traumatic brain injury. Clin Chim Acta, 2012,414 (12) : 12-17.
  • 4Hanaoka H , Okasaki Y , Satoh T , et al. Circulating anti-double-stranded DNA antibody-secreting cells in patients with systemic lupus erythematosus: a novel biomarker for disease act/vity. Lupus,2012,21 ( 12): 1284-1293.
  • 5Garca-Olmo D, Garca-Olmo DC, Domnguez-Berzosa C, et al. Oncogenic transformation induced by cell-free nucleic acids circulating in plasma (genometastasis) remains after the surgical resection of the primary tumor: apilot study. Expert Opin Biol Ther, 2012,12 (suppl 1 ): 61-68.
  • 6Boddy JL, Gal S, Malone PR, et al. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res, 2005, 11 (4) : 1394-1399.
  • 7廖新红,朱尚勇,杨红,何云,刘德云.前列腺系统活检结合血清PSA及经直肠超声对前列腺癌的诊断价值研究[J].中国超声医学杂志,2010,26(8):744-747. 被引量:9
  • 8Chun FK, Muller I, Lange I, et al. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU lm, 2006, 98( 3 ): 544-548.
  • 9Jung K, Stephan C, Lewandowski M, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett, 2004, 205(2):173-180.
  • 10Allen D, Butt A, Ca.hill D, et al. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann N Y Acad Sei, 2004, 1022( 6 ): 76-80.

二级参考文献8

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部